Less than two weeks after disclosing an upbeat but not very specific press release about phase III bioequivalence results comparing its version of albumin-bound paclitaxel, Cynviloq, to Celgene Corp.'s marketed blockbuster Abraxane, Sorrento Therapeutics Inc.'s potential $1.3 billion-plus deal with Nantworks Inc. gained what one analyst called a "huge validation" of the candidate's potential.